158 related articles for article (PubMed ID: 36222962)
21. A Multistage In Silico Study of Natural Potential Inhibitors Targeting SARS-CoV-2 Main Protease.
Elkaeed EB; Eissa IH; Elkady H; Abdelalim A; Alqaisi AM; Alsfouk AA; Elwan A; Metwaly AM
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955547
[TBL] [Abstract][Full Text] [Related]
22. Green and efficient one-pot three-component synthesis of novel drug-like furo[2,3-d]pyrimidines as potential active site inhibitors and putative allosteric hotspots modulators of both SARS-CoV-2 M
Mousavi H; Zeynizadeh B; Rimaz M
Bioorg Chem; 2023 Jun; 135():106390. PubMed ID: 37037129
[TBL] [Abstract][Full Text] [Related]
23. Inhibitor induced conformational changes in SARS-COV-2 papain-like protease.
Ferreira GM; Pillaiyar T; Hirata MH; Poso A; Kronenberger T
Sci Rep; 2022 Jul; 12(1):11585. PubMed ID: 35803957
[TBL] [Abstract][Full Text] [Related]
24. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
[TBL] [Abstract][Full Text] [Related]
25. [Bioactive compounds of Jingfang Granules against SARS-CoV-2 virus proteases 3CL
Shang ZP; Yi Y; Yu R; Fan JJ; Huang YX; Qiao X; Ye M
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):907-919. PubMed ID: 36241233
[TBL] [Abstract][Full Text] [Related]
26. SARS-CoV-2 Papain-Like Protease: Structure, Function and Inhibition.
Ullrich S; Nitsche C
Chembiochem; 2022 Oct; 23(19):e202200327. PubMed ID: 35993805
[TBL] [Abstract][Full Text] [Related]
27. Natural Products with Tandem Anti-inflammatory, Immunomodulatory and Anti-SARS-CoV/2 Effects: A Drug Discovery Perspective against SARS-CoV-2.
da Cunha LNOL; Tizziani T; Souza GB; Moreira MA; Neto JSS; Dos Santos CVD; de Carvalho MG; Dalmarco EM; Turqueti LB; Scotti MT; Scotti L; de Assis FF; Braga AL; Sandjo LP
Curr Med Chem; 2022; 29(14):2530-2564. PubMed ID: 34313197
[TBL] [Abstract][Full Text] [Related]
28. Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2.
Weglarz-Tomczak E; Tomczak JM; Talma M; Burda-Grabowska M; Giurg M; Brul S
Sci Rep; 2021 Feb; 11(1):3640. PubMed ID: 33574416
[TBL] [Abstract][Full Text] [Related]
29. Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
Tan H; Hu Y; Jadhav P; Tan B; Wang J
J Med Chem; 2022 Jun; 65(11):7561-7580. PubMed ID: 35620927
[TBL] [Abstract][Full Text] [Related]
30. Computer-aided drug design for the pain-like protease (PL
Gao H; Dai R; Su R
Biomed Pharmacother; 2023 Mar; 159():114247. PubMed ID: 36689835
[TBL] [Abstract][Full Text] [Related]
31. Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an
Awoonor-Williams E
Phys Chem Chem Phys; 2022 Oct; 24(38):23391-23401. PubMed ID: 36128834
[TBL] [Abstract][Full Text] [Related]
32. Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease.
Batool F; Mughal EU; Zia K; Sadiq A; Naeem N; Javid A; Ul-Haq Z; Saeed M
J Biomol Struct Dyn; 2022 May; 40(8):3777-3788. PubMed ID: 33251983
[TBL] [Abstract][Full Text] [Related]
33. In silico Studies on the Interaction between Mpro and PLpro From SARS-CoV-2 and Ebselen, its Metabolites and Derivatives.
Nogara PA; Omage FB; Bolzan GR; Delgado CP; Aschner M; Orian L; Teixeira Rocha JB
Mol Inform; 2021 Aug; 40(8):e2100028. PubMed ID: 34018687
[TBL] [Abstract][Full Text] [Related]
34. Virtual screening of phytoconstituents from miracle herb
Siddiqui S; Upadhyay S; Ahmad R; Gupta A; Srivastava A; Trivedi A; Husain I; Ahmad B; Ahamed M; Khan MA
J Biomol Struct Dyn; 2022 Jun; 40(9):3928-3948. PubMed ID: 33289456
[TBL] [Abstract][Full Text] [Related]
35. Some Flavolignans as Potent Sars-Cov-2 Inhibitors
Cetin A
Curr Comput Aided Drug Des; 2022; 18(5):337-346. PubMed ID: 35975852
[TBL] [Abstract][Full Text] [Related]
36. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
Abdizadeh R; Hadizadeh F; Abdizadeh T
Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
[TBL] [Abstract][Full Text] [Related]
37. Identifying Drug Candidates for COVID-19 with Large-Scale Drug Screening.
Wu Y; Pegan SD; Crich D; Lou L; Mullininx LN; Starling EB; Booth C; Chishom AE; Chang KY; Xie ZR
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901828
[TBL] [Abstract][Full Text] [Related]
38. Drug Repurposing for the SARS-CoV-2 Papain-Like Protease.
Cho CC; Li SG; Lalonde TJ; Yang KS; Yu G; Qiao Y; Xu S; Ray Liu W
ChemMedChem; 2022 Jan; 17(1):e202100455. PubMed ID: 34423563
[TBL] [Abstract][Full Text] [Related]
39. Finding potent inhibitors against SARS-CoV-2 main protease through virtual screening, ADMET, and molecular dynamics simulation studies.
Roy R; Sk MF; Jonniya NA; Poddar S; Kar P
J Biomol Struct Dyn; 2022 Sep; 40(14):6556-6568. PubMed ID: 33682642
[TBL] [Abstract][Full Text] [Related]
40. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
